The Food and Drug Administration (FDA) has cleared Dexcom G7 as an integrated continuous glucose monitoring (CGM) system. Tandem Diabetes Care is the first company to offer multiple insulin pumps, the Tandem Mobi system and t:slim X2 insulin pump, that integrate with the Dexcom G7 sensor. This pairing provides exceptional accuracy, optimizing insulin delivery.
The mean absolute relative difference (MARD) is a statistical measurement of how accurate a CGM system is, and a lower number indicates better accuracy. The Dexcom G7 sensor has an overall MARD of 8.2% for adults and 8.1% for children, compared to the Dexcom G6 CGM sensor, which has a MARD of 9% for overall users.1
Visit the Dexcom website for more detailed information about Dexcom G7 sensor glucose readings and how they help with diabetes management.
Reference
1. Dexcom G7 CGM System User Guide. 2024.
Important Note About CGM Support
Dexcom and Tandem have agreed which system issues are best handled by each company, including which company is responsible for reporting those events to the appropriate regulatory authority. To help ensure that the required reporting takes place in a timely fashion, customers may need to contact Dexcom for some issues and Tandem for others. Learn which continuous glucose monitoring (CGM) issues are specific to the sensor or the insulin pump, and which company to contact.
